AgingResearch.NewsJoin free

ARCA Biopharma

CompanyUnited StatesFounded 1992

RORWikidata

ARCA Biopharma develops 2 assets, the furthest in phase 2, no development reported (bucindolol hydrochloride in current or recent history of atrial fibrillation). Mostly small molecule and protein or enzyme acting on ADRB2, ADRB1 and ADRA1A; based in the United States, founded in 1992.

2
Assets
Furthest stage
Phase 2, no development reported
Raised
$57.9M
3
Trials
3
Signals

Pipeline

2

  • bucindolol hydrochloride

    Non-selective beta-adrenergic receptor antagonist with sympatholytic properties

    Phase 2, no development reported, Small molecule, ADRB2, ADRB1, current or recent history of atrial fibrillation

  • recombinant nematode anticoagulant protein c2

    Binds factor X or Xa to inhibit the tissue factor–factor VIIa complex and suppress coagulation.

    Phase 1, no development reported, Protein or enzyme, colon cancer

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms6
  • Trials3
  • Funding rounds and grants5
  • Deals9
  • Signals4
  • Similar companies6

Intelligence